Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: <i>In Vitro</i> and <i>In Vivo</i> Evidence

Abstract

Our findings provide a proof-of-principle that formulated synthetic miR-34a has therapeutic activity in preclinical models and support a framework for development of miR-34a-based treatment strategies in MM patients.